Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200472874> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4200472874 endingPage "S701" @default.
- W4200472874 startingPage "S701" @default.
- W4200472874 abstract "Abstract Background Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with activity against Enterobacterales producing class A, C and some class D β-lactamases. Resistance caused by these β-lactamases is especially high in ICUs. This study evaluated the in vitro activity of CAZ-AVI and comparators against Enterobacterales isolates from patients in ICU and non-ICU wards. Methods Non-duplicate clinical isolates were collected in 2017-2019 from patients in Asia/Pacific, Europe, Latin America, and Middle East/Africa. Susceptibility testing was performed using CLSI broth microdilution and interpreted using CLSI 2021 and FDA (tigecycline) breakpoints. PCR and sequencing were used to determine the β-lactamase genes present in all isolates with meropenem (MEM) MIC >1 µg/ml, and Escherichia coli, Klebsiella spp. and Proteus mirabilis with aztreonam or ceftazidime MIC >1 µg/ml. Results The activity of CAZ-AVI and comparators is shown in the table. Susceptibility rates among global Enterobacterales were generally lower for isolates from patients in ICU than non-ICU wards, but this difference was small for CAZ-AVI, which inhibited >96% of isolates from both ward types. Among MEM-nonsusceptible (NS) isolates, CAZ-AVI was active against 62.3% and 65.6% of ICU and non-ICU isolates, respectively, and 36.3% and 33.2%, respectively, carried metallo-β-lactamases (MBLs). CAZ-AVI inhibited >97% of MEM-NS MBL-negative isolates collected globally. Antimicrobial activity against all Enterobacterales from both ICU and non-ICU wards in Latin America (LA) was generally similar to the global average. Among MEM-NS isolates, antimicrobial activity of CAZ-AVI was >10 percentage points higher in LA than the global average among isolates from both ward types, at least partly because of a lower proportion of MBL-positive isolates in this subset (24.4% and 22.0% in ICU and non-ICUs, respectively). CAZ-AVI inhibited >98% of MEM-NS MBL-negative isolates from LA. Results Table Conclusion CAZ-AVI provides a valuable treatment option for infections caused by Enterobacterales that do not carry MBLs, including those from patients in ICU wards, where antimicrobial resistance is typically higher. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Gregory Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
- W4200472874 created "2021-12-31" @default.
- W4200472874 creator A5017159626 @default.
- W4200472874 creator A5020290756 @default.
- W4200472874 creator A5020992600 @default.
- W4200472874 creator A5038009031 @default.
- W4200472874 date "2021-11-01" @default.
- W4200472874 modified "2023-09-28" @default.
- W4200472874 title "1223. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales from ICU and Non-ICU Wards Collected in Latin America and Globally as part of the ATLAS Surveillance Program 2017-2019" @default.
- W4200472874 doi "https://doi.org/10.1093/ofid/ofab466.1415" @default.
- W4200472874 hasPublicationYear "2021" @default.
- W4200472874 type Work @default.
- W4200472874 citedByCount "0" @default.
- W4200472874 crossrefType "journal-article" @default.
- W4200472874 hasAuthorship W4200472874A5017159626 @default.
- W4200472874 hasAuthorship W4200472874A5020290756 @default.
- W4200472874 hasAuthorship W4200472874A5020992600 @default.
- W4200472874 hasAuthorship W4200472874A5038009031 @default.
- W4200472874 hasBestOaLocation W42004728741 @default.
- W4200472874 hasConcept C104317684 @default.
- W4200472874 hasConcept C176947019 @default.
- W4200472874 hasConcept C2775933652 @default.
- W4200472874 hasConcept C2776968632 @default.
- W4200472874 hasConcept C2777027569 @default.
- W4200472874 hasConcept C2777058267 @default.
- W4200472874 hasConcept C2777402170 @default.
- W4200472874 hasConcept C2777637488 @default.
- W4200472874 hasConcept C2779375183 @default.
- W4200472874 hasConcept C2779631663 @default.
- W4200472874 hasConcept C2780416669 @default.
- W4200472874 hasConcept C2780950330 @default.
- W4200472874 hasConcept C4937899 @default.
- W4200472874 hasConcept C501593827 @default.
- W4200472874 hasConcept C523546767 @default.
- W4200472874 hasConcept C54355233 @default.
- W4200472874 hasConcept C547475151 @default.
- W4200472874 hasConcept C55493867 @default.
- W4200472874 hasConcept C71924100 @default.
- W4200472874 hasConcept C86803240 @default.
- W4200472874 hasConcept C89423630 @default.
- W4200472874 hasConcept C94665300 @default.
- W4200472874 hasConceptScore W4200472874C104317684 @default.
- W4200472874 hasConceptScore W4200472874C176947019 @default.
- W4200472874 hasConceptScore W4200472874C2775933652 @default.
- W4200472874 hasConceptScore W4200472874C2776968632 @default.
- W4200472874 hasConceptScore W4200472874C2777027569 @default.
- W4200472874 hasConceptScore W4200472874C2777058267 @default.
- W4200472874 hasConceptScore W4200472874C2777402170 @default.
- W4200472874 hasConceptScore W4200472874C2777637488 @default.
- W4200472874 hasConceptScore W4200472874C2779375183 @default.
- W4200472874 hasConceptScore W4200472874C2779631663 @default.
- W4200472874 hasConceptScore W4200472874C2780416669 @default.
- W4200472874 hasConceptScore W4200472874C2780950330 @default.
- W4200472874 hasConceptScore W4200472874C4937899 @default.
- W4200472874 hasConceptScore W4200472874C501593827 @default.
- W4200472874 hasConceptScore W4200472874C523546767 @default.
- W4200472874 hasConceptScore W4200472874C54355233 @default.
- W4200472874 hasConceptScore W4200472874C547475151 @default.
- W4200472874 hasConceptScore W4200472874C55493867 @default.
- W4200472874 hasConceptScore W4200472874C71924100 @default.
- W4200472874 hasConceptScore W4200472874C86803240 @default.
- W4200472874 hasConceptScore W4200472874C89423630 @default.
- W4200472874 hasConceptScore W4200472874C94665300 @default.
- W4200472874 hasIssue "Supplement_1" @default.
- W4200472874 hasLocation W42004728741 @default.
- W4200472874 hasLocation W42004728742 @default.
- W4200472874 hasLocation W42004728743 @default.
- W4200472874 hasOpenAccess W4200472874 @default.
- W4200472874 hasPrimaryLocation W42004728741 @default.
- W4200472874 hasRelatedWork W2163292670 @default.
- W4200472874 hasRelatedWork W2896684631 @default.
- W4200472874 hasRelatedWork W2901057130 @default.
- W4200472874 hasRelatedWork W2981824984 @default.
- W4200472874 hasRelatedWork W2986528364 @default.
- W4200472874 hasRelatedWork W3118439655 @default.
- W4200472874 hasRelatedWork W4200267593 @default.
- W4200472874 hasRelatedWork W4200472874 @default.
- W4200472874 hasRelatedWork W4306644058 @default.
- W4200472874 hasRelatedWork W4376121438 @default.
- W4200472874 hasVolume "8" @default.
- W4200472874 isParatext "false" @default.
- W4200472874 isRetracted "false" @default.
- W4200472874 workType "article" @default.